TICKERNERD
Menu
GMEDGMEDHealthcare · Medical Devices

GMED Stock Forecast: Globus Medical, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$87
+9.40% on the day

The 14 Wall Street analysts covering Globus Medical, Inc. hold a median 12-month price target of $100 — +14.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 3 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$10.5B
Ticker Nerd rank
97/ 100
Median analyst target
$100
Analysts covering
14
Revenue$789.6M+5.9% y/y
Operating income$195.5M
Net income$151.6M
Free cash flow$176.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+7.1%
1M
+15.2%
YTD
−0.3%
1Y
+41.2%
From 52W high
−10.1%
From 52W low
+41.5%
$62
$97
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GMED stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Globus Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026
97/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
96
Value
95
Revisions
90
Momentum
81
Volatility
75
Growth
74
Issuance
67
Accruals
57
Size
14

Quality (96): The business earns solid, repeatable profits on what it owns.

Accruals (57): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GMED stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GMED, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120Jan 26Apr 26Jul 26Oct 26GMEDHigh $125Median $100Low $84

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
10 Buy4 Hold0 Sell
Low $84Median $100High $125

The green dot is the last close — the median target sits +14.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
1 Oct 2026RBC CapitalMaintainsOutperform$115 → $85
7 Aug 2026Wells FargoMaintainsOverweight—
7 Aug 2026Wells FargoMaintainsOverweight$103 → $99
28 July 2026UBSInitiatesNeutral—
28 July 2026UBSInitiatesNeutral$82
16 July 2026Truist SecuritiesMaintainsBuy$115 → $100
16 July 2026Truist SecuritiesMaintainsBuy—
13 July 2026RBC CapitalMaintainsOutperform$120 → $115
13 July 2026RBC CapitalMaintainsOutperform—
9 July 2026BMO CapitalInitiatesOutperform—
8 July 2026StifelMaintainsHold$95 → $80
8 July 2026StifelMaintainsHold—
15 June 2026Piper SandlerMaintainsOverweight—
8 May 2026NeedhamMaintainsBuy—
8 May 2026RBC CapitalMaintainsOutperform—
8 May 2026Wells FargoMaintainsOverweight—
26 Feb 2026Wells FargoMaintainsOverweight—
25 Feb 2026BarclaysMaintainsOverweight—
25 Feb 2026NeedhamMaintainsBuy—
30 Jan 2026NeedhamUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

GMED appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GMED vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Globus Medical, Inc. returned +41.2% against +14.8% for the S&P 500, dividends included.

GMED vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150160Jan 26Apr 26Jul 26Oct 26GMEDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GMED analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+5.5%
Analysts raising
13
Analysts cutting
0
Fundamentals

Globus Medical, Inc. (GMED) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
20.0×

Cheaper than 37% of US stocks

Price / sales
3.3×

Cheaper than 36% of US stocks

Price / book
2.2×

Cheaper than 39% of US stocks

EV / EBITDA
9.9×

Cheaper than 38% of US stocks

Growth & margins
Revenue growth (YoY)
5.9%

Higher than 43% of US stocks

Earnings growth (YoY)
−25.3%

Higher than 19% of US stocks

Gross margin
69.4%

Higher than 82% of US stocks

Operating margin
24.8%

Higher than 83% of US stocks

Net margin
17.0%

Higher than 80% of US stocks

Returns & dividend
Return on equity
11.8%

Higher than 67% of US stocks

Return on assets
8.7%

Higher than 90% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Globus Medical, Inc. (GMED) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Globus Medical, Inc. has a market value of $10.5B and an enterprise value of $10.0B.

  • Revenue in the twelve months to 30 June 2026: $3.1B. The latest quarter grew 5.9% year on year.

  • Net income over the same four quarters: $535.4M, a 17.0% net margin.

  • Diluted earnings per share, trailing twelve months: $3.91.

  • Free cash flow in the twelve months to 30 June 2026: $745.8M.

  • Globus Medical, Inc. spent $221.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 134.3M.

  • Trailing P/E: 20.0×; forward P/E: 14.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Globus Medical, Inc. employs 6,000 people — $524K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Nov 2026

Data provided by Twelve Data

Peers

GMED vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
GMEDGlobus Medical, Inc.$10.5B97
PODDInsulet Corp.$10.7B91
BIOBio-Rad Laboratories, Inc.$10.0B92
PENPenumbra, Inc.$12.6B76
BRKRBruker Corp.$8.6B90
TXG10X Genomics, Inc.$8.5B93
GKOSGlaukos Corp.$13.7B94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Globus Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GMED news & analysis

Globus Medical: The Shrinking Robot Line Hides A Growing Annuity

Seeking Alpha · 2 Nov 2026positive

Globus Medical is using flexible leasing to expand its installed base and emphasize recurring implant sales. The excerpt reports adjusted EBITDA margins of 35.4%, nearly doubled year-over-year free cash flow, and 25% growth in ExcelsiusGPS placements despite a segment revenue decline.

Why it matters — These developments point to a shift toward recurring sales and cash generation as GMED integrates NuVasive.

GMED vs. AXGN: Which Stock Should Value Investors Buy Now?

Zacks Investment Research · 2 Nov 2026neutral

Zacks Investment Research compares Globus Medical and AxoGen as Medical - Instruments stocks for investors evaluating potentially undervalued companies. The excerpt poses which may be the better option but provides no conclusion.

Why it matters — The comparison puts GMED in the context of a value-investing assessment alongside AXGN, without stating a preference in the excerpt.

Wall Street Analysts Think Globus Medical (GMED) Could Surge 30.52%: Read This Before Placing a Bet

Zacks Investment Research · 2 Nov 2026positive

Zacks reports that analysts’ consensus price target implies about 30.5% upside potential for Globus Medical. It notes that this metric has limited effectiveness, while upward earnings estimate revisions may signal near-term upside.

Why it matters — GMED watchers may want to note the reported price-target gap and earnings estimate trend, alongside the source’s caution about the metric’s reliability.

Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term

Zacks Investment Research · 2 Nov 2026positive

Zacks Investment Research presents Globus Medical as a top momentum stock for the long term and points readers to Zacks Style Scores as a way to identify stocks for an investment portfolio.

Why it matters — GMED watchers may note the article’s favorable momentum framing and its reference to Zacks Style Scores.

2 Healthcare Technology Stocks for a Digital Health Boom

Zacks Investment Research · 29 Oct 2026positive

Zacks Investment Research identified GMED and STE as healthcare technology stocks offering exposure to sector growth, citing projected 2026 EPS gains, attractive valuations, and innovation in essential medical services.

Why it matters — The item highlights GMED’s connection to healthcare technology growth and notes projected earnings gains and valuation appeal.

FAQ

Frequently asked questions about GMED stock

What is the GMED stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Globus Medical, Inc. have a median 12-month price target of $100, with estimates ranging from $84 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GMED stock a buy right now?

Of the 14 analysts covering Globus Medical, Inc., 10 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Globus Medical, Inc. 97 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GMED?

As at 3 Nov 2026, Globus Medical, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).

Will GMED stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +14.9% from the last close, and Ticker Nerd's factor model ranks Globus Medical, Inc. 97 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GMED stock forecast for 2030?

No analyst covering Globus Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GMED are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $84 to $125 over the next 12 months.

How has GMED stock performed over the past year?

Globus Medical, Inc. returned +41.2% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Globus Medical, Inc. do?

Globus Medical Inc. Class A Common Stock represents ownership in Globus Medical, a medical device company focused on musculoskeletal care.

What is the latest news on GMED?

The most recent item we track (Seeking Alpha, 2 Nov 2026): "Globus Medical: The Shrinking Robot Line Hides A Growing Annuity". Globus Medical is using flexible leasing to expand its installed base and emphasize recurring implant sales. The excerpt reports adjusted EBITDA margins of 35.4%, nearly doubled year-over-year free cash flow, and 25% growth in ExcelsiusGPS placements despite a segment revenue decline.

Company

About Globus Medical, Inc.

Globus Medical Inc. Class A Common Stock represents ownership in Globus Medical, a medical device company focused on musculoskeletal care. The company develops and commercializes products for spine and orthopaedic applications, including implant systems, surgical instruments, and enabling technologies used in hospitals, physician practices, and surgical centers. Its portfolio supports procedures for spinal disorders, bone healing, and other complex musculoskeletal conditions, making it a significant supplier in the healthcare equipment market. Globus Medical also provides integrated solutions that combine devices, instrumentation, and technology to support surgical workflows and patient treatment. Headquartered in Audubon, Pennsylvania, Globus Medical serves healthcare providers in the United States and internationally.

CEO Mr. Keith W. Pfeil · 6,000 employees · United States · https://www.globusmedical.com